FDA completes its review of Lannett's IND for biosimilar insulin glargine

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News

BioBlast w/e 26 May 23

by Naomi Pearce, Sian Hope | May 29, 2023

26 MAY 2023 | EU | Celltrion files MAA with EMA for biosimilar to Janssen’s Stelara® (ustekinumab) Korea Biomed has reported that Celltrion filed a...

Beware the shifting sands of patent term extensions (PTE) in Australia

by Naomi Pearce, Eliza Jane Saunders, Chris Vindurampulle | May 25, 2023

Recent Australian decisions have resulted in both new opportunities to challenge patent term extensions in Australia and new patent prosecution...

BioBlast w/e 22 May 23

by Naomi Pearce, Sian Hope | May 23, 2023

22 MAY 2023 | US | Janssen and Amgen settle Stelara® (ustekinemab) biosimilar patent dispute The US District Court of Delaware has dismissed with...

Pearce IP leaders recognised as 2023 MIP Patent Stars

by Pearce IP | May 23, 2023

Pearce IP congratulates two of its leaders, Founder and CEO Naomi Pearce, and Special Counsel Jacinta Flattery-O’Brien PhD, who were honoured this...

BioBlast w/e 12 May 23

by Naomi Pearce, Sian Hope | May 15, 2023

11 MAY 2023| EU | Celltrion to supply Vegzelma® (bevacizumab) in Italy and Belgium Korea Biomed has reported that Celltrion Healthcare has won bids...